Skip to content

Sana Biotechnology SANA Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.3%+2.2pp
Gilead Sciences logo
Gilead SciencesGILD
5.9%-1.1pp
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-8.8%-1.3pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-20.5%-5.1pp
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-24%-8.4pp

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$912.8M+54.1%
Enterprise value$904.32M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Calculated from Sana Biotechnology’s reported figures.

Based on trailing twelve months.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's free cash flow yield?
Sana Biotechnology (SANA) reported free cash flow yield of -17.4% in Q1 2026.
How has Sana Biotechnology's free cash flow yield changed year-over-year?
Sana Biotechnology's free cash flow yield increased by 70.6% year-over-year, from -59.2% to -17.4%.
What is the long-term trend for Sana Biotechnology's free cash flow yield?
Over 4 years (2021 to 2025), Sana Biotechnology's free cash flow yield has grown at a 8.2% compound annual growth rate (CAGR), from -9.8% to -13.4%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.